Isosorbide mononitrate with nadolol compared to nadolol alone for prevention of the first bleeding in cirrhosis. A double-blind placebo-controlled randomised trial

Gastroenterology International

Volumn 15, Issue 3-4, 2002, Pages 40-50

  D'Amico, Gennaro ^a   Pasta, L ^b   Politi, F ^b   Vizzini, G ^b   Traina, M ^b   Caltagirone, M ^b   Patti, R ^b   Madonia, S ^b   Pagliaro, L ^b  

^a VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^b NONE

Author keywords

Esophageal varices; Gastrointestinal hemorrhage; Liver cirrhosis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ISOSORBIDE MONONITRATE; NADOLOL; PLACEBO; PROPRANOLOL;

ADULT; ARTICLE; ASCITES; ASTHENIA; ASTHMA; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MIXTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS VARICES BLEEDING; FEMALE; FOLLOW UP; HEADACHE; HEART FAILURE; HEMATEMESIS; HIGH RISK PATIENT; HUMAN; HYPOTENSION; INCIDENCE; LIVER CIRRHOSIS; MALE; MAXIMUM TOLERATED DOSE; MELENA; MONOTHERAPY; MUSCLE WEAKNESS; NAUSEA; PATIENT COMPLIANCE; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT FAILURE; VERTIGO;

EID: 0141681316     PISSN: 09505911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Pagliaro L, D'Amico G, Pasta L, Politi F, Vizzini G, Traina M, et al. Portal hypertension in cirrhosis: natural history. In: Bosch J, Groszmann R, editors. Portal hypertension: Pathophysiology and treatment. Cambridge, MA: Blackwell Scientific; 1994. p.72-92.
2. D'Amico G, Luca A. Natural history. Clinical-haemodynamic correlations. Prediction of the risk of bleeding. In: Bosch J, editor. Portal hypertension. Bailliere's Clinical Gastroenterology (London) 1997;11:243-56.
3. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence based approach. Sem Liver Dis 1999;19:475-505.
4. Grace ND, Garcia-Pagan JC, Angelico M, Groszman RJ, Merkel C, Moreau R, et al. Baveno III Consensus Statements: Primary prophylaxis. In: De Franchis R, editor. Portal hypertension III. Proceedings of the Third Baveno International Consensus Workshop on definitions, methodology, and therapeutic strategies. Oxford: Blackwell Science; 2001. p. 132-3.
5. Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M, et al. Hemodynamic events in a prospective randomised trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990;99:1401-7.
6. Feu F, Garcia-Pagan JC, Bosch J, Luca A, Terés J, Escorsell A, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995;346:1056-9.
7. Garcia-Tsao G, Groszmann RJ. Portal hemodynamics during nitroglycerine administration in cirrhotic patients. Hepatology 1987;7:805-9.
8. Merkel C, Finucci G, Zuin R, Bazzerla G, Bolognesi M, Sacerdoti D, et al. Effects of isosorbide dinitrate on portal hypertension in alcoholic patients. J Hepatol 1987;4:174-80.
9. Navasa M, Chesta J, Bosch J, Rodes J. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamic and liver function. Gastroenterology 1989;96:1110-8.
10. Garcia-Pagan JC, Navasa M, Bosch J, Bru C, Pizcueta P, Rodes J. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. Hepatology 1990;11:230-8.
11. Garcia-Pagan JC, Feu F, Bru C, Ruiz del Arbol L, Bosch J, Rodes J. Long term hemodynamic effects of isosorbide 5-mononitrate in patients with cirrhosis and portal hypertension. J Hepatol 1990;11:189-95.
12. Garcia-Pagan JC, Feu F, Bosch J, Rodes J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann Int Med 1991;114:869-73.
13. Merkel C, Marin R, Enzo E, Donada C, Vallarin G, Torboli P, et al. Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Lancet 1996:348:1677-81.
14. Spanish Variceal Bleeding Study Group. Propranolol+placebo vs propranolol+Isosorbide -5-mononitrate in the prevention of the first variceal bleeding. A multicenter double-blind randomized controlled trial. [Abstract] J Hepatol 1999;30(Suppl 1):55.
15. Patti R, D'Amico G, Pasta L, Vizzini G, Traina M, Madonna S, et al. Isosorbide mononitrate with nadolol compared to nadolol alone for prevention of recurrent bleeding in cirrhosis. A double-blind placebo-controlled randomised trial. [Abstract] J Hepatol 1999;30(Suppl 1):81.
16. Pietrosi G, D'Amico G, Pasta L, Patti R, Vizzini G, Traina M, Madonna S, et al. Isosorbide mononitrate with nadolol compared to nadolol alone for prevention of first bleeding in cirrhosis. A double-blind placebo controlled randomised trial. [Abstract]. J Hepatol 1999;30(Suppl 1):66.
17. The Italian Liver Cirrhosis Project. Reliability of endoscopy in the assessment of variceal features. J Hepatol 1987;4:93-8.
18. Zoli M, Merkel C, Magalotti D, Marchesini G, Gatta A, Pisi E. Evaluation of a new endoscopic index to predict first bleeding from the upper gastrointestinal tract in patients with cirrhosis. Hepatology 1996;24:1047-52.
19. Beppu K, Inokuchi K, Koyanagi N, Nakayama S, Sakata H, Kitano S, et al. Prediction of variceal hemorrhage by esophageal endoscopy. Gastrointest Endosc 1981;27:213-8.
20. Pugh RNH, Murray-Lyon M, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
21. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-70.
22. Pagliaro L, de Franchis R. Where were we? A summary of the issues where consensus was reached at Baveno I. In: de Franchis R, editor. Portal Hypertension II. Proceedings of the Second Baveno International Consensus Workshop on definitions, methodology and therapeutic strategies. Oxford: Blackwell Science; 1996. p. 1-9.
23. North Italian Endoscopic Club for the study and treatment of esophageal varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 1988;319:983-9.
24. Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley, 1989.
25. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation. II. Analysis and examples. Br J Cancer 1977;35:1-39.
26. Cox DR. The analysis of binary data. London: Methuen; 1970.
27. Harrell FE Jr, Lee KL, Matchar DB, Reichert T. Regression models for prognostic prediction: advantages, problems and suggested solutions. Cancer Treat Rep 1985;69:1071-7.
28. Gournay J, Masilah C, Martin T, Perrin D, Galmiche JP. Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. Hepatology 2000;31:1239-45.
29. Gin-Ho Lo, Wen-Chi Chen, Mei-Hsiu Chen, Ping-I Hsu, Chiun-Ku Lin, Wei-Lun Tsai, Kwok-Hung Lai. Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding. Gastroenterology 2002;123:728-34.
30. Patch D, Sabin CA, Goulis J, Greensdale L, Merkel C, Burroughs AK. A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology. 2002;123:1013-9.
31. Villanueva C, Balanzò J, Novella MT, Soriano G, Sainz S, Torras X, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996;334:1624-9.
32. Villanueva C, Minana J, Ortiz J, Gallego A, Soriano G, Torras X, et. al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001;345:647-55.
33. Lui HF, Stanley AJ, Forrest HE, Jalan R, Hislop WS, Mills PR, et al. Primary prophylaxis of variceal hemorrhage: a randomised controlled trial comparing band ligation, propranolol and isosorbide mononitrate. Gastroenterology 2002;123:735-44.
34. Salmeron JM, del Arbol LR, Gines A, Garcia-Pagan JC, Gines P, Feu F, et al. Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis. Hepatology 1993;17:800-6.
35. Morillas MR, Planas R, Cabré E, Galan A, Quer JC, Feu F, et al. Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. Long-term hemodynamic and renal effects. Hepatology 1994;20:1502-8.
36. Vorobioff J, Picabea E, Gamen M, Villavincencio R, Bordato J, Bessone F, et al. Propranolol compared with propranolol plus isosorbide dinitrate in portal-hypertensive patients: long-term hemodynamic and renal effects. Hepatology 1993;18:477-84.
37. Merkel C, Gatta A, Donada C, Enzo E, Marin R, Amodio P, et al. Long-term effect of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis. Hepatology 1995;22:808-13.
38. Merkel C, Marin R, Sacerdoti D. Long-term results of a clinical trial of Nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. [Abstract] Hepatology 1999;30:215A.